INS-3001 Weekly Dosing Schedule to Limit Tissue Accumulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing dosing schedules for inositol polyphosphate oligo(ethylene glycol) derivatives do not effectively inhibit the formation or exposure to calcium phosphate precipitates in tissues, particularly in cardiovascular and renal tissues, and daily administration leads to accumulation issues.
Innovation Solution
Administering inositol polyphosphate oligo(ethylene glycol) compounds at weekly intervals or longer spaced intervals, with specific dosing ranges for human subjects, to prevent or treat conditions associated with calcium salt crystal formation or exposure, including renal fibrosis, nephritis, and cardiovascular calcification.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inositol polyphosphate oligo(ethylene glycol) derivatives are administered daily, then therapeutic effect is maintained, but compound accumulation occurs in tissues
Solution Approach 1:
The patent applies periodic action by transitioning from daily administration to weekly or longer spaced intervals (every 1-4 weeks) for administering inositol polyphosphate oligo(ethylene glycol) derivatives. This periodic dosing schedule maintains therapeutic effectiveness while preventing compound accumulation in tissues, as the extended intervals allow the body to clear the compound between doses while still providing sufficient exposure to inhibit calcium phosphate precipitate formation.
2Quantity of substance
If inositol polyphosphate oligo(ethylene glycol) derivatives are administered at weekly intervals, then compound accumulation is reduced, but dosing frequency decreases
Solution Approach 1:
The patent implements periodic action with extended intervals between doses, specifically weekly or longer spaced intervals (every 1-4 weeks), which reduces compound accumulation while maintaining therapeutic effect. This approach accepts reduced dosing frequency as a necessary trade-off to achieve safe accumulation levels, and the patent demonstrates that this reduced frequency is sufficient to maintain therapeutic effectiveness in preventing calcium phosphate precipitate formation.
3Ease of operation
If dosing intervals are extended to weekly or longer, then treatment simplicity increases, but risk of inadequate coverage between doses increases
Solution Approach 1:
The patent applies periodic action by establishing specific dosing intervals of weekly or longer spaced intervals (every 1-4 weeks), which simplifies treatment regimens while maintaining therapeutic coverage. The patent demonstrates through preclinical data that these extended intervals are sufficient to maintain effective drug levels and prevent calcium phosphate precipitate formation, thereby resolving the contradiction between treatment simplicity and therapeutic reliability.
Data Source
Figure 1(A)~1(B)
Figure 2(A)~2(B)
Figure 3
AI summary
The invention relates to a dosing schedule for an inositol polyphosphate oligo(ethylene glycol) compound, or its pharmaceutically acceptable salt used in the treatment or prevention of a disease associated with formation of, and/or tissue exposure to, calcium salt crystals. The drug compound is administered at an interval of one week.